Patents by Inventor Louis Jungheim

Louis Jungheim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20070293423
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 18, 2004
    Publication date: December 20, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Louis Jungheim, John McGill, III, Kenneth Thrasher, Robert Herr, Muralikrishna Valluri
  • Tachykinin receptor antagonists
    Publication number: 20060160794
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
    Type: Application
    Filed: June 3, 2004
    Publication date: July 20, 2006
    Inventors: Albert Amegadzie, Kevin Gardinier, Erik Hembre, Philip Hipskind, Louis Jungheim, Brian Muehl, Kenneth Savin, Keneth Thrasher, Steven Boyd
  • Tachykinin receptor antagonists
    Publication number: 20050239776
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 27, 2005
    Applicant: Eli Lilly and Company
    Inventors: Albert Amegadzie, Kevin Gardinier, Erik Hembre, Jian Hong, Louis Jungheim, Brian Muehl, David Remick, Michael Robertson, Kenneth Savin
  • Triazole derivatives as tachykinin receptor antagonists
    Publication number: 20050239786
    Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 27, 2005
    Applicant: Eli Lilly Company
    Inventors: Albert Amegadzie, Kevin Gardinier, Erik Hembre, Jian Hong, Louis Jungheim, Brian Muehl, David Remick, Michael Robertson, Kenneth Savin